Publications by authors named "Adrian Bagust"

Claim this Profile
L
Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
Nigel Fleeman, Rachel Houten, Adrian Bagust, Marty Richardson, Sophie Beale

Health Technol Assess· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Nigel Fleeman, Adrian Bagust, Rui Duarte, Marty Richardson, Sarah Nevitt

Pharmacoecon Open· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Angela Stainthorpe, Janette Greenhalgh, Adrian Bagust, Marty Richardson, Angela Boland

Pharmacoeconomics· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the Effects of Early Censoring and Analysis of Clinical Trial Survival Data on Effectiveness and Cost-effectiveness Estimation through a Case Study in Advanced Breast Cancer.
Adrian Bagust, Sophie J Beale

Med Decis Making· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Nigel Fleeman, Ahmed Abdulla, Adrian Bagust, Sophie Beale, Marty Richardson

Pharmacoeconomics· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Nigel Fleeman, Adrian Bagust, Angela Boland, Sophie Beale, Marty Richardson

Pharmacoeconomics· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
Nigel Fleeman, Adrian Bagust, Sophie Beale, Angela Boland, Rumona Dickson

Pharmacoeconomics· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale

Health Technol Assess· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.
Gerlinde Pilkington, Angela Boland, Tamara Brown, James Oyee, Adrian Bagust

Thorax· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Janette Greenhalgh, Adrian Bagust, Angela Boland, Kerry Dwan, Sophie Beale

Health Technol Assess· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin for the treatment of advanced or metastatic breast cancer: a NICE single technology appraisal.
Janette Greenhalgh, Adrian Bagust, Angela Boland, James Oyee, Nicola Trevor

Pharmacoeconomics· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab in combination with trastuzumab and docetaxel for the treatment of HER2-positive metastatic or locally recurrent unresectable breast cancer.
Nigel Fleeman, Adrian Bagust, Sophie Beale, Kerry Dwan, Rumona Dickson

Pharmacoeconomics· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival analysis and extrapolation modeling of time-to-event clinical trial data for economic evaluation: an alternative approach.
Adrian Bagust, Sophie Beale

Med Decis Making· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal.
Sophie Beale, Rumona Dickson, Adrian Bagust, Michaela Blundell, Yenal Dundar

Pharmacoeconomics· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisal.
Janette Greenhalgh, Adrian Bagust, Angela Boland, Michaela Blundell, James Oyee

Pharmacoeconomics· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving valuation sampling of EQ-5D health states.
Adrian Bagust

Health Qual Life Outcomes· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal.
Rumona Dickson, Adrian Bagust, Angela Boland, Michaela Blundell, Helen Davis

Pharmacoeconomics· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
Adrian Bagust, Janette Greenhalgh, Angela Boland, Nigel Fleeman, Claire McLeod

Pharmacoeconomics· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-eluting stents versus bare metal stents for angina or acute coronary syndromes.
Janette Greenhalgh, Juliet Hockenhull, Naveen Rao, Yenal Dundar, Rumona C Dickson, Adrian Bagust

Cochrane Database Syst Rev· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The average body surface area of adult cancer patients in the UK: a multicentre retrospective study.
Joseph J Sacco, Joanne Botten, Fergus Macbeth, Adrian Bagust, Peter Clark

PLoS One· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.
Joost Daemen, Maarten L Simoons, William Wijns, Adrian Bagust, Gert Bos, A Bagust

Eur Heart J· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
Joost Daemen, Maarten L Simoons, William Wijns, Adrian Bagust, Gert Bos

EuroIntervention· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Sorrel E Wolowacz, David A Cameron, Helen C Tate, Adrian Bagust

J Clin Oncol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Philip Home, Adrian Bagust, Matthew Taylor, Philip Ambery, Samara Mendes da Costa

Pharmacoeconomics· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis